Cargando…

PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases

BACKGROUND: Programmed death-ligand 1 (PD-L1) regulates immune homeostasis by promoting T-cell exhaustion. It is involved in chronic infections and tumor progression. Nuclear imaging using radiolabeled anti-PD-L1 antibodies can monitor PD-L1 tissue expression and antibody distribution. However, phys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandker, Gerwin G. W., Adema, Gosse, Molkenboer-Kuenen, Janneke, Wierstra, Peter, Bussink, Johan, Heskamp, Sandra, Aarntzen, Erik H. J. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960984/ https://www.ncbi.nlm.nih.gov/pubmed/35359962 http://dx.doi.org/10.3389/fimmu.2022.837370

Ejemplares similares

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
por: Wierstra, Peter, et al.
Publicado: (2019)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents
por: Hagemans, Iris M., et al.
Publicado: (2022)

Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris
por: Hagemans, Iris M., et al.
Publicado: (2022)

Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models
por: Boreel, Daan F., et al.
Publicado: (2023)

Elucidating the Influence of Tumor Presence on the Polymersome Circulation Time in Mice
por: de Kruijff, Robin M., et al.
Publicado: (2019)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Characterization of Intrinsically Radiolabeled Poly(lactic-co-glycolic acid) Nanoparticles for ex Vivo Autologous Cell Labeling and in Vivo Tracking
por: Krekorian, Massis, et al.
Publicado: (2021)

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier
por: Kruijff, R. M. de, et al.
Publicado: (2019)

Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy
por: van Genugten, Evelien A. J., et al.
Publicado: (2022)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients
por: Heskamp, Sandra, et al.
Publicado: (2015)

Response Monitoring with [(18)F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases
por: Heskamp, Sandra, et al.
Publicado: (2016)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
por: Garousi, Javad, et al.
Publicado: (2019)

Imaging of T-cells and their responses during anti-cancer immunotherapy
por: Krekorian, Massis, et al.
Publicado: (2019)

Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models
por: Huizing, Fokko J., et al.
Publicado: (2021)

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models
por: Huizing, Fokko J., et al.
Publicado: (2018)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
por: Zalba, Sara, et al.
Publicado: (2020)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models
por: Huizing, Fokko J., et al.
Publicado: (2019)

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
por: Bussing, David, et al.
Publicado: (2021)

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies
por: Ogasawara, Ken, et al.
Publicado: (2019)

Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2021)

Dendritic cell vaccination and immune monitoring
por: Aarntzen, E. H. J. G., et al.
Publicado: (2008)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
por: Ho, Nataschja I., et al.
Publicado: (2018)

Pharmacokinetics of anti-infectious reagents in silkworms
por: Hamamoto, Hiroshi, et al.
Publicado: (2019)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients
por: Aarntzen, EHJG, et al.
Publicado: (2010)

The role of dendritic cells in the pathogenesis of systemic lupus erythematosus
por: Fransen, Justin H, et al.
Publicado: (2010)

Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96
por: Boch, Christina, et al.
Publicado: (2022)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters
por: Aarntzen, Erik H. J. G., et al.
Publicado: (2012)

MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?
por: Hörner-Rieber, Juliane, et al.
Publicado: (2021)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Assessing health status and quality of life of Q-fever patients: the Nijmegen Clinical Screening Instrument versus the Short Form 36
por: van Loenhout, Joris AF, et al.
Publicado: (2013)

Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation
por: Huis in ’t Veld, Lisa G. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elj0fmn2l9t5fukf1cimqbpj85